AbbVie doses first subject in adalimumab clinical trial using Halozyme's ENHANZE tech
Halozyme Therapeutics, Inc. today announced that AbbVie has dosed the first subject in a clinical trial evaluating the safety and pharmacokinetics of adalimumab with Halozyme's proprietary ENHANZE technology.